Search

Displaying results 1421 - 1430 of 10000 in total
  1. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.

  2. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.

  3. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
  4. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

  5. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

  6. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.

  7. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

    Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamine
  8. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  9. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    has been carried out in CEF cells only. … [A237520, L36050] Although TICOVAC was originally based on a master seed virus passaged in mouse brain and then propagated in chicken embryo fibroblast (CEF) cells, since the 1990's, the whole process

    Products: FSME-Immun 0,25 ml Junior Injektionssuspension in einer Fertigspritze, FSME-Immun 0,5 ml Erwachsene Injektionssuspension in einer Fertigspritze
  10. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition